AngioDynamics Releases 10-Q Report; Shares Surge by 11.5%

By Tamara Parker • Wednesday, April 02 15:16 • Permanent Link

AngioDynamics, Inc. has recently released its 10-Q report, detailing its financial performance and operations for the quarter and nine months ended February 28, 2025. The company, founded in 1988 and headquartered in Latham, New York, is a medical technology firm that designs, manufactures, and sells a variety of medical, surgical, and diagnostic devices for treating peripheral vascular disease and oncology, as well as in surgical settings.

In the 10-Q report, the company's Management's Discussion and Analysis of Financial Condition and Results of Operations highlights the impact of the current macroeconomic environment on its business. It outlines the company's restructuring plan to shift to an outsourced manufacturing model, as well as the approval of a share repurchase program and the sale of manufacturing facilities in Queensbury, NY, and Glens Falls, NY.

The report provides a comprehensive overview of the company's financial performance, with key figures for the three and nine months ended February 28, 2025, compared to the same periods in the prior year. It reveals that for the three months ended February 28, 2025, revenue decreased by 4.2% to $72.0 million, and for the nine months ended February 28, 2025, revenue decreased by 8.8% to $212.3 million. The company's net loss decreased by $183.3 million to $4.4 million for the three months ended February 28, 2025, and by $143.0 million to $27.9 million for the nine months ended February 28, 2025.

The 10-Q report also provides a breakdown of net sales, with the Med Tech segment experiencing growth of 21.3% and the Med Device segment declining by 17.6% for the three months ended February 28, 2025. Additionally, the report outlines the factors contributing to the changes in sales, including increased Auryon and thrombus management platform sales, as well as decreased sales of PICCs, Midlines, and RadioFrequency Ablation products.

The market has reacted to these announcements by moving the company's shares 11.5% to a price of $10.77. For more information, read the company's full 10-Q submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.